Entering text into the input field will update the search result below

Sage Therapeutics to report topline data from mid-stage study of SAGE-217 in PPD in Q4

Feb. 08, 2018 6:05 AM ETSage Therapeutics, Inc. (SAGE) StockSAGEBy: Douglas W. House, SA News Editor
  • Sage Therapeutics (NASDAQ:SAGE) reports that it expects to announce topline data from a Phase 2 clinical trial evaluating SAGE-217 in women with postpartum depression (PPD) in Q4.
  • SAGE-217, a neuroactive steroid, is next-generation GABA modulator. The GABA system, the major inhibitory signaling pathway in the brain and central nervous system (CNS), plays a key role in regulating CNS function.
  • It also expects the $575M proceeds from its planned stock offering, along with cash on hand and expected sales from brexolone IV, to be sufficient to fund operations into 2020.
  • Previously: Sage Therapeutics launches mid-stage study of SAGE-217 in PPD (Dec. 19, 2016)

Recommended For You

More Trending News

About SAGE Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SAGE--
Sage Therapeutics, Inc.